Prenetics to Participate in the 38th Annual ROTH Conference
Rhea-AI Summary
Prenetics (NASDAQ: PRE) will attend the 38th Annual ROTH Conference in Laguna Niguel, CA, March 22–24, 2026. Management will hold one-on-one investor meetings and participate in a fireside chat at 8:30 a.m. PT and a Consumer Influencer panel at 12:00 p.m. PT on Monday, March 23, 2026. Both sessions will be available via webcast on the company’s investor relations website. To schedule meetings, investors should contact Investor Relations or their ROTH representative.
Positive
- None.
Negative
- None.
News Market Reaction – PRE
On the day this news was published, PRE declined 1.30%, reflecting a mild negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $365M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PRE fell 4.6% with light volume while at least 2 peers (e.g., BNR -2.97%, PRPO -4.6%) also moved down. Scanner data flags a broader sector downside move (median peer move -3.8%).
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 06 | Share repurchase plan | Positive | +18.1% | Authorized a $40M share repurchase with strong liquidity and no debt. |
| Mar 03 | Insider share purchases | Positive | -3.5% | Executives completed a second round of post-earnings open-market share buys. |
| Feb 23 | Product launch | Positive | -8.4% | Launched IM8 Daily Ultimate Essentials PRO with higher potency and new flavors. |
| Feb 23 | Asset sale, liquidity | Positive | -7.7% | Completed $70M Insighta sale, boosting total adjusted liquidity to $171.1M. |
| Feb 18 | Earnings results | Positive | -7.7% | Reported record FY2025 results with ~480% YoY revenue growth and strong IM8 ARR. |
Recent news has been mostly positive, yet 4 of 5 prior events saw negative next-day price reactions, suggesting a pattern of selling into good news.
Over the last few months, Prenetics announced several balance-sheet and growth milestones, including record FY2025 revenue, strategic divestitures lifting total adjusted liquidity to $171.1M, and a $40M share repurchase authorization alongside management open-market stock purchases. Product expansion continued with the IM8 Daily Ultimate Essentials PRO launch. Despite generally positive fundamentals, four of the last five news events saw negative 24-hour price reactions, indicating a tendency for shares to pull back following good news. Today’s conference-participation update fits into this ongoing investor re-pricing of prior gains.
Market Pulse Summary
This announcement highlights Prenetics’ participation in the 38th Annual ROTH Conference from March 22–24, with management hosting a fireside chat at 8:30 a.m. PT and joining a panel at 12:00 p.m. PT. It adds investor-relations visibility rather than new financial data. In context of recent balance-sheet strengthening, rapid IM8 growth, and a new buyback authorization, investors may focus on how conference discussions reinforce or clarify these previously disclosed milestones and timelines.
AI-generated analysis. Not financial advice.
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (PRE) (“Prenetics” or the “Company”), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced the Company will participate in the 38th Annual ROTH Conference being held Sunday, March 22nd to Tuesday, March 24th at the Ritz-Carlton in Laguna Niguel, CA.
Prenetics CEO Danny Yeung and President of Americas David Vanderveen will be available for one-on-one meetings throughout the conference. Management will also participate in a fireside chat at 8:30 a.m. PT and a Consumer Influencer panel discussion at 12:00 p.m. PT on Monday, March 23rd — both available via webcast at the links above and on the Company’s investor relations website.
To schedule a one-on-one meeting with Prenetics’ management, please contact Investor Relations at PRE@mzgroup.us or your ROTH representative.
About Prenetics
Prenetics (NASDAQ: PRE) is a leading health sciences company dedicated to advancing human health and longevity. The Company’s flagship consumer brand, IM8, co-founded with David Beckham and championed by World No. 1 tennis player Aryna Sabalenka, is redefining the premium daily nutrition category through science-backed formulations and global brand partnerships. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, achieving an impressive milestone of surpassing
About IM8
IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com.
Investor Relations Contact:
investors@prenetics.com
PRE@mzgroup.us
Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com
FAQ
When will Prenetics (PRE) present at the 38th Annual ROTH Conference?
How can investors schedule one-on-one meetings with Prenetics (PRE) at ROTH?
Will Prenetics (PRE) provide a webcast of its ROTH Conference sessions?
Which Prenetics executives will attend the ROTH Conference representing PRE?
What topics will Prenetics (PRE) cover at the ROTH Conference sessions?
Where and when is the 38th Annual ROTH Conference that Prenetics (PRE) will attend?
